HIV and Tuberculosis: A Formidable Alliance

HIV-associated tuberculosis is a significant cause of infection-related death, affecting one in every three HIV deaths and over 300,000 in 2017. The HIV epidemic has complicated tuberculosis-control efforts, and the management of HIV-associated TB is complex due to rapid clinical progression, immune reconstitution inflammatory syndrome, drug-drug interactions, and shared toxicities. HIV and Tuberculosis: A Formidable Alliance is a comprehensive resource that provides well-rounded and thorough coverage of this topic, appealing to researchers and clinicians.

Format: Paperback / softback
Length: 347 pages
Publication date: 12 May 2022
Publisher: Springer Nature Switzerland AG

Globally, HIV-associated tuberculosis (TB) stands as a paramount cause of infection-related mortality, accounting for one in every three HIV-related deaths and exceeding 300,000 cases in 2017 alone. The HIV epidemic has posed significant challenges to tuberculosis control efforts across numerous countries worldwide, as the virus exerts profound modifying effects on the pathogenesis, diagnosis, and treatment of TB. Moreover, the management of HIV-associated TB is further intricate due to the rapid clinical progression, immune reconstitution inflammatory syndrome, drug-drug interactions, and shared toxicities. Over the past two decades, a vast body of research publications and review articles has been generated on HIV-associated TB. In response, HIV and Tuberculosis: A Formidable Alliance has emerged as a comprehensive resource, consolidating this immense body of data into a single, accessible platform. This book, authored by a diverse array of experts from epidemiology, immunology, public health, and clinical medicine, offers a well-rounded and thorough coverage that will captivate both researchers and clinicians alike.

The prevalence of HIV-associated TB is particularly concerning in low- and middle-income countries, where the co-infection rates are highest. In these regions, the dual burden of HIV and TB poses a significant threat to public health, leading to prolonged illness, disability, and reduced quality of life. The interaction between HIV and TB is complex and multifaceted, with the virus exacerbating the immune response to TB, thereby hindering the effectiveness of treatment. Additionally, the presence of HIV infection increases the risk of developing drug-resistant TB, further complicating the management of the disease.

The diagnosis of HIV-associated TB is challenging due to the overlap of symptoms and signs with those of both HIV and TB. Moreover, the presence of HIV can interfere with the diagnostic tests used for TB, leading to false-negative results. Therefore, comprehensive screening and testing strategies are essential in identifying individuals at risk of HIV-associated TB. Treatment of HIV-associated TB requires a multidisciplinary approach, combining antiretroviral therapy (ART) with TB treatment. ART not only suppresses the replication of HIV but also improves the immune response to TB, thereby enhancing the effectiveness of TB treatment.

However, the treatment of HIV-associated TB is not without its challenges. The use of certain anti-TB drugs, such as rifampin and isoniazid, can interact with ART, leading to drug-drug interactions and potentially severe side effects. Additionally, the immune reconstitution inflammatory syndrome, a common complication of HIV-associated TB, can cause severe inflammation and organ damage, requiring close monitoring and management.

Despite these challenges, significant progress has been made in the management of HIV-associated TB over the past few decades. The development of new diagnostic tools, such as nucleic acid amplification tests (NAATs), has improved the accuracy and sensitivity of TB diagnosis. Moreover, the introduction of novel TB treatment regimens, such as shorter treatment courses and combination therapies, has enhanced the effectiveness of TB treatment.

In conclusion, HIV-associated TB remains a significant global health concern, with profound implications for public health and individual well-being. The HIV epidemic has undermined tuberculosis-control efforts, highlighting the need for comprehensive and coordinated efforts to address this dual burden. By consolidating research and expertise, HIV and Tuberculosis: A Formidable Alliance provides a valuable resource for researchers, clinicians, and policymakers in the fight against HIV-associated TB. Through a multidisciplinary approach, we can enhance our understanding of the disease, improve diagnostic strategies, and develop effective treatment regimens to reduce the impact of this formidable alliance on global health.

Weight: 551g
Dimension: 235 x 155 (mm)
ISBN-13: 9783030291105
Edition number: 1st ed. 2019